HERVolution Therapeutics is advancing immunotherapies targeting antigens encoded in the “dark genome,” specifically human endogenous retroviruses (HERVs) such as HERV-K. These normally silenced antigens become aberrantly expressed in chronic inflammation, metabolic stress, cancer, and aging—driving immune evasion, senescence, and cardiometabolic dysfunction. By breaking immune tolerance to HERV-K, HERVolution is developing differentiated, off-the-shelf therapies that sit at the intersection of immunology, inflammation, cardiometabolic disease, oncology, and longevity. This work directly aligns with BIO BIGS themes on high-impact immunology investments and the need to differentiate next-generation cardiometabolic and longevity pipelines through novel biology and first-in-class mechanisms.